Sight Sciences Boosts Revenue Guidance on Strong Glaucoma and Dry…

Event summary

Sight Sciences reported Q2 2026 revenue of $23.4M, up 20% YoY, driven by 8% growth in Interventional Glaucoma and a 704% surge in Interventional Dry Eye revenue.
The company raised its full-year 2026 revenue guidance to $88M–$92M (up from $83M–$89M) and reduced adjusted operating expense guidance to $92M–$94M.
Aetna expanded coverage for Sight Sciences' Interventional Glaucoma procedures, adding ~25M commercial covered lives retroactive to July 14, 2026.
FDA cleared the OMNI® Ultra Surgical System with TruSync™ Plus technology in Q2 2026.

The big picture

Sight Sciences' strong Q2 performance reflects growing adoption of interventional eye care, particularly in the dry eye segment. The company's ability to secure expanded insurance coverage and regulatory clearances positions it to capitalize on shifting treatment paradigms in ophthalmology. With improved gross margins and disciplined cost management, Sight Sciences is poised to compete more aggressively in a market increasingly focused on minimally invasive solutions.

What we're watching

Market Expansion: Whether Sight Sciences can sustain the rapid growth in Interventional Dry Eye revenue, which surged 704% YoY.
Regulatory Tailwinds: How the FDA clearance of OMNI Ultra and Aetna's expanded coverage will impact adoption rates for glaucoma treatments.
Operational Efficiency: The pace at which Sight Sciences can reduce adjusted operating expenses while scaling commercial efforts in dry eye and standalone glaucoma markets.